Two-Drug HIV pill works well in teens, cuts side effects
NCT ID NCT03682848
First seen Jan 05, 2026 · Last updated May 23, 2026 · Updated 26 times
Summary
This study tested a once-daily pill containing two HIV drugs (dolutegravir and lamivudine) in 32 teens aged 12 to 18 who had never taken HIV medication before. The goal was to see if this simpler two-drug regimen could safely control the virus after 48 weeks. Results showed the pill effectively suppressed HIV, offering a way to reduce long-term side effects from more complex drug combinations. Since HIV requires lifelong treatment, this is a disease-control approach, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Kericho, 20200, Kenya
-
GSK Investigational Site
Kisumu, 40100, Kenya
-
GSK Investigational Site
Cape Town, 7500, South Africa
-
GSK Investigational Site
Durban, 4001, South Africa
-
GSK Investigational Site
Johannesburg, 1862, South Africa
-
GSK Investigational Site
Bangkok, 10330, Thailand
-
GSK Investigational Site
Bangkok, 10700, Thailand
-
GSK Investigational Site
Chiang Mai, 50200, Thailand
Conditions
Explore the condition pages connected to this study.